Check for updates

Outer Membrane Vesicles From The Gut Microbiome Contribute to Tumor Immunity by Eliciting Cross-Reactive T Cells

Michele Tomasi[1†], Elena Caproni[1†], Mattia Benedet[1,2†], Ilaria Zanella[1], Sebastiano Giorgetta[1], Mattia Dalsass[1], Enrico König[1,2], Assunta Gagliardi[2], Laura Fantappiè[2], Alvise Berti[1], Silvia Tamburini[1], Lorenzo Croia[1], Gabriele Di Lascio[1], Erika Bellini[2], Silvia Valensin[2], Giada Licata[3,4], Guido Sebastiani[3,4], Francesco Dotta[3,4,5], Federica Armanini[1], Fabio Cumbo[1], Francesco Asnicar[1], Aitor Blanco-Míguez[1], Eliana Ruggiero[6], Nicola Segata[1], Guido Grandi[1*] and Alberto Grandi[2,7*]

[1] Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy, [2] Toscana Life Sciences Foundation, Siena, Italy, [3] Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy, [4] Fondazione Umberto Di Mario, c/o Toscana Life Sciences Foundation, Siena, Italy, [5] Tuscany Centre for Precision Medicine (CReMeP), Siena, Italy, [6] Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS) Ospedale San Raffaele, Milan, Italy, [7] BiOMViS Srl, Siena, Italy

A growing body of evidence supports the notion that the gut microbiome plays an important role in cancer immunity. However, the underpinning mechanisms remain to be fully elucidated. One attractive hypothesis envisages that among the T cells elicited by the plethora of microbiome proteins a few exist that incidentally recognize neo-epitopes arising from cancer mutations ("molecular mimicry (MM)" hypothesis). To support MM, the human probiotic *Escherichia coli* Nissle was engineered with the SIINFEKL epitope (OVA-*E.coli* Nissle) and orally administered to C57BL/6 mice. The treatment with OVA-*E.coli* Nissle, but not with wild type *E. coli* Nissle, induced OVA-specific CD8$^+$ T cells and inhibited the growth of tumors in mice challenged with B16F10 melanoma cells expressing OVA. The microbiome shotgun sequencing and the sequencing of TCRs from T cells recovered from both *lamina propria* and tumors provide evidence that the main mechanism of tumor inhibition is mediated by the elicitation at the intestinal site of cross-reacting T cells, which subsequently reach the tumor environment. Importantly, the administration of Outer Membrane Vesicles (OMVs) from engineered *E. coli* Nissle, as well as from *E. coli* BL21 (DE3)Δ*ompA*, carrying cancer-specific T cell epitopes also elicited epitope-specific T cells in the intestine and inhibited tumor growth. Overall, our data strengthen the important role of MM in tumor immunity and assign a novel function of OMVs in host-pathogen interaction. Moreover, our results pave the way to the exploitation of probiotics and OMVs engineered with tumor specific-antigens as personalized mucosal cancer vaccines.

Keywords: outer membrane vesicles, cancer, microbiome, cancer vaccines, molecular mimicry

INTRODUCTION

The gut microbiome plays a fundamental role in cancer immunity and in determining the efficacy of cancer immunotherapy (1). A recent epidemiological study has shown that antibiotic-associated dysbiosis can enhance the frequency of certain cancers, including lung, prostate and bladder cancers (1, 2). Furthermore, it was shown that C57BL/6 germ-free or microbiome-depleted mice respond poorly to PD-1/PD-L1 therapy, while the anti-tumor activity of checkpoint inhibitors is potentiated when *Bifidobacterium* species are administered by oral gavage after tumor challenge (3). Moreover, transplantation of fecal microbiome from patients responding to PD-L1 therapy, but not from non-responders, improves the efficacy of checkpoint inhibitors both in animal models and in melanoma patients (2, 4, 5). Finally, retrospective analyses in human patients under PD-1/PD-L1 therapy show the deleterious effect of antibiotics administered during the monoclonal antibody treatment (1).

The mechanisms through which the gut microbiome influences cancer immunity are poorly defined. Three non-mutually exclusive mechanisms have been proposed. First, the gut microbiome has been shown to release metabolites, such as polyamine, vitamin B16 and short-chain fatty acids, which mediate systemic effect on the host immunity (6). A second mechanism envisages a long distance adjuvant effect, which the microbiome exerts by releasing products and cytokines (1, 3, 7–9). The third mechanism assumes that gut microbiome antigens are continuously processed by resident DCs, which in turn induce epitope-specific T cells. This T cell population mainly resides in the intestinal epithelium [intraepithelial lymphocytes (IELs)] and in the *lamina propria*, but can eventually disseminate systemically and reach organs and tumors (4). Considering the abundance and diversity of microbial immunogenic epitopes, it is conceivable to believe that some of them induce T cells capable of recognizing homologous neo-epitopes arising from cancer mutations ("molecular mimicry (MM)" hypothesis). The MM hypothesis is particularly attractive since it would assign a previously unpredicted specificity to the anti-tumor activity of the gut microbiome.

The experimental evidence supporting the role of cross-reactive epitopes is still limited. It has been shown that the rare (<2%) long term (>10 years) survivors of pancreatic cancer carry infiltrating cytotoxic T cells specific for a MUC16 neo-epitope and T cells that cross-react with pathogen-associated epitopes (10). Moreover, bioinformatics analysis of the gut microbiome has revealed the existence of several microbiome antigens with high homology to known immunogenic T cell epitopes of bacterial, viral, and allergic antigens. This has led to propose the existence of microbiome "tolerogenic" and "inflammatory" epitopes which can dampen or increase the immunogenicity toward the homologous antigen-specific T cell epitopes (11, 12). More recently, it has been proposed that mimic peptides from commensal bacteria can promote inflammatory cardiomyopathy in genetically susceptible individuals, leading to myocarditis and lethal heart disease (13). Moreover, *Bifidobacterium breve* was shown to carry a T cell epitope, which cross-reacts with a model

neo-antigen present in B16.SIY melanoma cell line and that the presence of *B. breve* in the mouse intestine reduced the growth of B16.SIY tumors in C57BL/6 mice (14). Finally, mice bearing the tail length tape measure protein (TMP) found in the genome of a *Enterococcus hirae* bacteriophage mounted a TMP-specific CD8[+] T cell response, which improved PD-1 immunotherapy (15).

Demonstrating the role of MM in cancer immunity is somehow challenging. Using animal models, one possible approach we are currently testing (16) is to (i) sequence the microbiome pan-genome from mice resistant to a tumor challenge, (ii) scan the predicted pan-proteome in search of a microbial species carrying sequences homologous to known immunogenic cancer epitope(s), and (iii) prove that the presence of such microbial species elicits epitope-specific T cells and inhibits tumor growth. An alternative strategy is to (i) "force" a commensal bacterium to express a protein carrying an amino acid sequence homologous (or identical) to a specific cancer epitope, then (ii) administer the engineered strain to mice by oral gavage, and finally (iii) test whether epitope-specific T cells are elicited at the mucosal site and whether the growth of a tumor expressing such epitope is inhibited. In this work we have engineered the human commensal *E. coli* Nissle with the MHC I-restricted OVA epitope and we show that the delivery of the strain into the intestine of C57BL6 mice promotes the elicitation of OVA-specific T cells and protects mice from the challenge of ovalbumin-expressing B16 melanoma tumor (**Figure 1A**). We also show that Outer Membrane Vesicles (OMVs) decorated with the OVA peptide inhibit tumor growth both in a prophylactic and a therapeutic modality.

MATERIALS AND METHODS

Bacterial Strains, Cell Lines and Mouse Strains

DH5α, HK100 were used for cloning experiments. *Escherichia coli* Nissle 1917 (EcN) was isolated from the probiotic EcN[®] (Cadigroup, Rome, Italy) and *E. coli* BL21(DE3)Δ*ompA* was produced in our laboratory (17). *E. coli* strains were grown in LB at 37°C or 30°C in static or shaking conditions (200 rpm). When required, LB was supplemented with 50 μg/ml kanamycin, 25 μg/ml chloramphenicol, 0.2% L-arabinose and 5% sucrose. Stock preparations of *E. coli* strains in LB 20% glycerol were stored at -80°C.

OVA-B16F10 cell line, a B16F10 cell line transfected with a plasmid carrying a complete copy of chicken ovalbumin (OVA) cDNA and the Geneticin (G418) resistance gene, was kindly provided by Cristian Capasso and Prof. Vincenzo Cerullo from the Laboratory of Immunovirotherapy, Drug Research Program, Faculty of Pharmacy, University of Helsinki. OVA-B16F10 cell line was cultured in RPMI supplemented with 10% FBS, penicillin/streptomycin/L-glutamine and 5 mg/ml Geneticin[™] (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and grown at 37°C in 5% CO_2. C57BL/6 or BALB/c female 4-8 week old mice were purchased from Charles River Laboratories and kept and treated in accordance with the Italian policies on

animal research at the animal facilities of Toscana Life Sciences, Siena, Italy and Department of Cellular, Computational and Integrative Biology (CIBIO) – University of Trento, Italy. Mice were caged in groups of 5/8 animals in ventilated cages. Mice within the same cage received the same treatment.

Engineering EcN and *E. coli* BL21(DE3) ΔompA Strains With CD8$^+$ T Cell Epitopes

The pCRISPR-*lpp*-sgRNA plasmid, used for EcN mutagenesis, is a derivative of pCRISPR-*sacB* and codifies for a synthetic small guide RNA (sgRNA) (18). The *lpp*-sgRNA is composed by a 20 nt guide specific for *lpp*, a 42 nt Cas9-binding hairpin (Cas9 handle) and a 40 nt transcription terminator of *S. pyogenes* (**Supplementary Table 1**) (19). For the construction of pCRISPR-*lpp*-sgRNA, a DNA fragment containing the *rrnB* T1 transcription terminator, the -10 and -35 consensus sequences of the J23119 promoter and the *lpp*-sgRNA chimera (**Supplementary Table 1**) was synthesized by GeneArt (Thermo Fisher Scientific, Waltham, MA, USA) and cloned in pCRISPR-*sacB* using AvrII and XhoI restriction sites, thus replacing the gRNA cassette. The pCRISPR-*lpp*-gRNA plasmid, used for BL21(DE3)Δ*ompA* mutagenesis, is a derivative of pCRISPR-*sacB* in which a 30 nt DNA sequence coding for an *lpp*-gRNA guide specific for *lpp* is cloned using MB1360 and MB1361 oligonucleotides (**Supplementary Table 2**) as described previously (18). Both pCRISPR-*lpp*-sgRNA and pCRISPR-*lpp*-gRNA contain a polylinker cloned into pCRISPR-*sacB* by PIPE-PCR with primers MB1346 and MB1347 and transformation in *E. coli* HK100 competent cells. The *lpp*-OVA donor DNA (dDNA) (**Supplementary Table 1**) was chemically synthesized (GeneArt, Thermo Fisher Scientific, Waltham, MA, USA) with termini carrying the XhoI and NsiI restriction site sequences. It contains an EcN genomic region of 231 bp upstream from the *lpp* stop codon, followed by the OVA sequence flanked by restriction sites (NheI, Not and NdeI) and an EcN genomic region of 397 bp downstream from the *lpp* stop codon. In the arm upstream to OVA, the *lpp* TAC codon (Tyr), placed 9 bp upstream to the TAA stop codon, has been changed into TAT (Tyr) in order to eliminate the PAM sequence placed 5 bp upstream to the stop codon.

The construction of pET21-MBP-AH1 plasmid expressing the *E. coli* Maltose Binding protein (MBP) fused to three repeated copies of AH1 peptide linked by a Glycine–Serine (GS) spacers (**Supplementary Table 3**) was obtained from pET21-MBP (20) by ligating the AH1 DNA fragment carrying the BamHI/XhoI flags.

The pET21-FhuD2-SV40 plasmid carrying the *Staphylococcus aureus* Ferric hydroxamate receptor 2 (FhuD2) fused to one copy of SV40 IV peptide (21, 22), was assembled using the PIPE method (23). Briefly, pET21-FhuD2 was linearized by PCR, using FhuD2-v-R and pET-V-F primers (**Supplementary Table 2**). In parallel, the synthetic DNA encoding one copy of SV40 IV epitope (**Supplementary Table 3**) was amplified by PCR with the forward FhuD2-SV40-F and the reverse FhuD2-SV40-R primers (**Supplementary Table 2**). The PCR products were mixed together and used to transform *E. coli* HK100 strain.

To confirm the correct gene fusions, plasmids were sequenced (Eurofins, Ebersberg, Germany, EU) and *E. coli* BL21 (DE3)Δ*ompA* strain was transformed with pET21-MBP-AH1 and pET21-FhuD2-SV40 plasmids and the derived recombinant strain was used for the production of engineered MBP-AH1 and FhuD2-SV40 OMVs, respectively.

EcN(pCas9λred) and BL21(DE3)Δ*ompA*(pCas9λred) strains and competent cells were prepared as described previously (18). For genome engineering, 50 µl of EcN(pCas9λred) or BL21 (DE3)Δ*ompA*(pCas9λred) competent cells were co-transformed with 100 ng of pCRISPR-*lpp*-sgRNA or pCRISPR-*lpp*-gRNA, respectively, and with 200 ng of dDNA. Cells were then incubated at 30°C (200 rpm) for 3 hours, plated on LB agar supplemented with chloramphenicol and kanamycin and incubated overnight at 37°C. The day after, single colonies were screened by colony PCR to identify clones carrying the OVA sequence insertion at the 3'-end of the *lpp* gene. Primers MB1336 and *lpp*2 (**Supplementary Table 2**) were designed to anneal upstream and downstream the insertion site, thus generating amplicons of different lengths in the presence of *lpp*-OVA (609 nt) or wt *lpp* (549 nt). Positive clones were cured from pCRISPR-*sacB* derivative plasmids and from pCas9λred as described previously (18). The correctness of the *lpp*-OVA gene sequence was verified by sequencing using primers MB1336, *lpp*1, *lpp*2, MB1337, MB1390 (**Supplementary Table 2**).

OMV Preparation

OMVs from EcN and EcN(*lpp*-OVA) were prepared growing the strains in an EZ control bioreactor (Applikon Biotechnology, Schiedam, Netherlands) as previously described (24). Cultures were started at an OD$_{600}$ of 0.1 and grown until the end of the exponential phase at 30°C, pH 6.8 (± 0.2), dO2 > 30%, 280–500 rpm. OMVs were then purified and quantified as previously described (24). BL21(DE3)Δ*ompA* and BL21(DE3)Δ*ompA*(*lpp*-OVA) were grown at 37°C and 180 rpm in LB medium (starting OD$_{600}$ = 0.1) and when the cultures reached an OD$_{600}$ value of 0.4-0.6 were maintained at 37°C under agitation for two additional hours. Finally, the purification of OMVs from BL21 (DE3)Δ*ompA*(pET-MBP-AH1) and BL21(DE3)Δ*ompA*(pET-FhuD2-SV40) was carried out growing the cultures at OD$_{600}$ = 0.5, adding 0.1 mM IPTG and continuing the incubation for 2 h at 37°C.

Culture supernatants were separated from biomass by centrifugation at 4000g for 20 minutes. After filtration through a 0.22-µm pore size filter (Millipore, Burlington, Massachusetts, USA), OMVs were isolated, concentrated and diafiltrated from the supernatants using Tangential Flow Filtration (TFF) with a Cytiva Äkta Flux system. OMVs were quantified using DC protein assay (Bio-Rad, Hercules, California. USA)

OVA-Specific CD8$^+$ T Cells Analysis in Lamina Propria and Tumor Tissue

For the analysis of T cells in the *lamina propria*, C57BL/6 or BALB/c mice were given bacteria (10^9 CFUs) or OMVs (10 µg) by oral gavages at day 0, day 3 and 6 and at day 15 mice were

sacrificed and small intestines were collected. In a first step, the intraepithelial lymphocytes (IELs) were dissociated from the mucosa by shaking the tissue in a pre-digestion solution, using the Lamina Propria Dissociation kit (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer's instruction. Then the *lamina propria* tissue was treated enzymatically and mechanically dissociated into a single-cell suspension by using the gentleMACS[TM] Dissociators (Miltenyi Biotech, Bergisch Gladbach, Germany).

Tumor-infiltrating lymphocytes were isolated from subcutaneous OVA-B16F10 tumors as follows. Tumors (at least two tumors per group) were collected and minced into pieces of 1–2 mm of diameter using a sterile scalpel, filtered using a Cell Strainer 70 μm and transferred into 50-ml tubes. Then, the tumor tissue was enzymatically digested using the Tumor Dissociation kit (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer's protocol and the gentleMACS[TM] Dissociators were used for the mechanical dissociation steps. After dissociation, the sample was passed through to a 30 μm filter to remove larger particles from the single-cell suspension.

At the end of the dissociation protocol, $1-2 \times 10^6$ cells from *lamina propria* and tumors were incubated with 5 μl of Dextramer-PE (OVA (SIINFEKL), SV40 (VVYDFLKL) and AH1 (SPSYVHQF), IMMUDEX, Virum, Denmark) for 10 minutes at room temperature in a 96-well plate. As negative control the unrelated dextramer SSYSYSSL was used (IMMUDEX, Virum Denmark). Then, cells were incubated with NearIRDead cell staining Kit (Thermo Fisher, Waltham, MA, USA) 20 minutes on ice in the dark. After two washes with PBS, samples were re-suspended in 25 μl of anti-mouse CD16/CD32-Fc/Block (BD Bioscience, San Jose, CA, USA), incubated 15 minutes on ice and then stained at RT in the dark for 20 minutes with the following mixture of fluorescent-labeled antibodies: CD3-APC (Biolegend, San Diego, CA), CD4-BV510 (Biolegend, San Diego, CA) and CD8a-PECF594 (BD Bioscience, San Jose, CA, USA). After two washes with PBS, cells were fixed with Cytofix (BD Bioscience, San Jose, CA, USA) for 20 minutes on ice, then washed twice and re-suspended in PBS. Samples were analyzed using a BD LSRII and the raw data were elaborated using *FlowJo* software. For the evaluation of the percentage of CD8[+]/OVA[+] T cells in *lamina propria* and tumors the following gating strategy was applied. After selection of NearIRDead - cells (live cells) and identification of FSC (forward scatter) and SSC (side scatter) morphology typical for the T cell population, only the SSW- cells (singlets) were selected and analyzed. This population was first separated in CD3[+] and CD3[-] cells and the CD3[+] population was subsequently discriminated as CD4[+] and CD8[+] cells. Double positive CD8[+]/OVA[+] T cells were finally selected.

OVA-Specific CD8[+] T Cells Analysis in Spleen and PBMCs

Mice were immunized following the same schedule and protocol used for T cell analysis in the *lamina propria*. At day 15 mice were sacrificed for collection of spleens and whole blood. Spleens were homogenized and splenocytes filtered using a Cell Strainer 70 mm. After centrifugation at 400 x g for 7 minutes, splenocytes were suspended in PBS and aliquoted in a 96-well plate at a concentration of 1×10^6 cells per well.

After sampling, the whole blood was mixed with heparin (25 USP units/sample) and diluted 1:1 in volume with PBS. 2 ml of Ficoll-Paque (GE Healthcare, Chicago Illinois, USA) was placed at the bottom of a conical tube, and blood was then slowly layered above, then samples are centrifuged at 400g for 30 minutes. After centrifugation the ring formed by the PBMCs was removed carefully and aliquoted in a 96-well plate at a concentration of 1×10^6 cells per well.

Splenocytes and PBMCs were stimulated with 10 μg/ml of an unrelated peptide (negative control), or 10 μg/ml of OVA peptide. As positive control, cells were stimulated with phorbol 12-myristate 13-acetate (PMA, 0.5 ng/ml) and Ionomycin (1 μg/ml). After 2 hours of stimulation at 37°C, Golgi-Stop (BD Bioscience, San Jose, CA, USA) was added to each well and cells incubated for 4 h at 37°C. After two washes with PBS, NearIRDead cell staining reaction mixture (Thermo Fisher, Waltham, MA, USA) was incubated with the splenocytes for 20 minutes at room temperature in the dark. After two washes with PBS and permeabilization and fixing with Cytofix/Cytoperm (BD Bioscience, San Jose, CA, USA) using the manufacturer's protocol, splenocytes were stained with a mix of the following fluorescent-labelled antibodies: Anti CD3-APC (Biolegend, San Diego, CA), Anti-CD4-BV510 (Biolegend, San Diego, CA), anti-CD8-PECF594 (BD) and IFNγ-BV785 (Biolegend, San Diego, CA). Samples were analyzed on a BD LSRII FACS using FlowJo software. Graphs were processed with Prism 5.0 software (Graphpad).

Mouse Tumor Models

Bacteria (10^9 CFUs) and OMVs (10 μg) were given to C57BL/6 mice by oral gavage in 100 μl volume (PBS). C57BL/6 animals were subcutaneously challenged with 2.8×10^5 OVA-B16F10 cells. Tumor growth was followed for at least 25 days after challenge and tumor volumes were determined with a caliper using the formula $(A \times B^2)/2$, where A is the largest and B the smallest diameter of the tumor. For the therapeutic protocol, mice were first challenged with 2.8×10^5 OVA-B16F10 cells and subsequently treated with oral gavages (bacteria or OMVs) as described above. Tumor growth was monitored for at least 25 days. Statistical analysis (unpaired, two-tailed Student's t-test) and graphs were processed using GraphPad Prism 5.03 software.

Immunofluorescence

Tumors from sacrificed mice were collected and maintained in RPMI on ice. Subsequently were embedded in Tissue-Tek OCT compound and frozen with isopentane (VWR, Radnor, Pennsylvania, USA) kept in dry ice. Seven-μm thick sections were cut from frozen OCT blocks, using Leica CM1950 Cryostat. For antigen-specific T-cell detection, frozen sections were firstly incubated with 0.5% Bovine Serum Albumin in PBS (BSA, Sigma-Aldrich, St. Louis, MO, USA) followed by an overnight incubation at +4°C with anti-OVA$_{257-264}$ Dextramer PE conjugate (SIINFEKL, IMMUDEX, Virum Denmark) diluted

1:30 in blocking solution. Then sections were fixed with PBS 2% paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA) and incubated with polyclonal Rabbit anti- PE (Abcam, Cambridge, UK) diluted 1:1.000 in PBS for 1 hour at room temperature. Subsequently, sections were incubated with goat anti-Rabbit Alexa-Fluor 488 conjugate (Molecular Probe, Waltham, MA, USA) diluted 1:500 in PBS, for 1 hour at room temperature. Sections were counterstained with 4′,6- Diamidino-2-phenylindole di-hydrochloride (DAPI, Sigma-Aldrich, St. Louis, MO, USA) diluted 1:3.000 in PBS, and then mounted with Dako Fluorescence mounting medium (Dako, Agilent Technologies, Santa Clara, CA, USA) and stored at +4°C until ready for image analysis. In order to confirm the specificity of the dextramer staining, a single immunofluorescence staining was performed to evaluate the effective presence of $CD8^+$ cells. After an overnight air-drying step, frozen sections (see above) were fixed in Acetone (VWR, Radfonor, Pennsylvania, USA) for 10 minutes, air-dried for 20 minutes and incubated with 5% goat serum in PBS (Sigma-Aldrich, St. Louis, MO, USA) to block non-specific reactions. Then, sections were incubated for 30 minutes at room temperature with a rat monoclonal antibody anti-Mouse CD8 (BD Pharmingen, BD Bioscience, San Jose, CA, USA) diluted 1:50 in blocking solution. Subsequently, sections were incubated for 1 hour at room temperature with goat anti-rat Alexa-Fluor 488 conjugate antibody (Molecular Probe, ThermoFisher Scientific Waltham, MA, USA) diluted 1:500 in PBS.

$FoxP3^+$ T cells were detected using immunofluorescence as previously described (25–27). After an overnight air-drying step, frozen sections of collected tumors were fixed in Acetone (VWR, Radnor, Pennsylvania, USA) for 10 minutes, air-dried for 30 minutes and incubated with Tris Buffered Saline pH 7.6, supplemented with protease inhibitor (cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail, Roche, Basel, Switzerland) and 5% BSA for 30 minutes to block non-specific reactions. Then, sections were incubated overnight at 4°C with Rat monoclonal antibody anti-Mouse FoxP3-FITC conjugate (eBioscience, Thermo Fisher Scientific, Waltham, MA, USA) diluted 1:100 in blocking solution. The next day, sections were incubated for 45 minutes at room temperature with secondary antibody polyclonal Rabbit anti-Fluorescein/Oregon green Alexa-Fluor 488 conjugate (Molecular Probe, ThermoFisher Scientific Waltham, MA, USA) diluted 1:80 in blocking solution; and with tertiary antibody Goat anti-Rabbit Alexa-Fluor 488 conjugate (Molecular Probe, ThermoFisher Scientific Waltham, MA, USA) diluted 1:266 in blocking solution. Finally, sections were counterstained with DAPI, and mounted with Dako Fluorescence mounting medium as described above. Whole slide fluorescence images were acquired using Nanozoomer S60 automated slidescanner (Hamamatsu, Hamamatsu City, Japan). Positive cells were manually counted using NDP View2 Plus software (Hamamatsu, Hamamatsu City, Japan) on a total of 6 sections/tumor for $CD8^+$ and OVA^+ T cell count (covering a tissue depth of ~300 μm) and 10 sections/tumor for $FoxP3^+$ T cell count (covering a tissue depth of ~500 μm). Total number of positive cells and area of tissue sections were measured, and cells density calculated as number of positive cells/mm^2.

TCR Sequencing

At the end of the dissociation protocol (as described above), $CD8^+$ cells from *lamina propria* and tumors were magnetically labeled with CD8 MicroBeads (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer's manual. Then, the cell suspension was loaded onto a MACS® Column, which was placed in the magnetic field of a MACS Separator. The magnetically labeled $CD8^+$ T cells were retained within the column and eluted after removing the column from the magnetic field. At the end of separation, 5-8×10^3 $CD8^+$ T cells from *lamina propria* or 15-20×10^3 $CD8^+$ T cells from tumors were processed for the RNA extraction using the Arcturus® PicoPure® RNA Isolation Kit (Thermo Fisher, Waltham, MA, USA) according to the manufacturer's protocol.

Complementarity determining region (CDR) 3 sequences of the TCR β chain were amplified by using a RACE approach (28). Samples were sequenced by using an Illumina MiSeq sequencer and CDR3 clonotypes identified using the MiXCR software (29). Sequences retrieved only once were excluded from the analysis. Normalized Shannon-Wiener index and Inverse Simpson index were calculated using the VDJtools package (PMID: 26606115). For comparing diversity indices between samples, original data were down-sampled to the size of the smallest dataset.

GLIPH2 algorithm (30) was employed to identify clusters of TCR sequences predicted to bind the same MHC-peptide. For this analysis, mMouse CD8 TCR set was selected as reference dataset and all amino acid were considered as interchangeable.

Shotgun Whole Genome Sequencing of the Gut Microbiome

Bacteria or OMVs were administered to mice by oral gavage with 100 μl of PBS containing 10^9 bacteria cells or 10μg of OMVs, respectively. Fecal samples were collected before the first gavage (T_0), before tumor challenge (T_1) and when animals were sacrificed (T_2). Total DNA was purified from collected feces using the Quick-DNA Fecal/Soil Microbe Miniprep Kit (Zymo Research, Irvine, Canada, USA) according to the manufacturer's instruction and subjected to shotgun sequencing. Sequencing libraries were prepared using the Illumina® DNA Prep, (M) Tagmentation kit (Illumina, San Diego, California, USA), following the manufacturer's guidelines. A cleaning step on the pool with 0.6× Agencourt AMPure XP beads was implemented. Sequencing was performed on a Novaseq600 S4 flowcell (Illumina, San Diego, California, USA) at the internal sequencing facility at University of Trento, Trento, Italy. Metagenomic shotgun sequences were quality filtered using trim galore discarding all reads of quality <20 and shorter than 75 nucleotides. Filtered reads were then aligned to the human genome (hg19) and the PhiX genome for human and contaminant DNA removal using Bowtie 2, v.2.2.8 (31), yielding an average of 40 million bases in high-quality reads in each sample. Species-level microbial abundances were obtained through the bioBakery suite of tools using MetaPhlAn v.4.0 (32)

with default settings (database January 2021). Relative abundances at species level were analyzed in R. Beta diversity was calculated using the Bray-Curtis distance. Differential abundant species between T_0/T_1 and T_0/T_2 were discovered using a non-paired Wilcoxon test and selected based on a $P < 0.05$.

SDS-PAGE and Western Blot Analysis

In order to prepare total lysates, bacteria were grown in LB broth to an OD_{600} of 0.5, pelleted in a bench-top centrifuge and resuspended in Laemmli loading buffer to normalize cell density to a final OD_{600} of 10. OMVs were prepared as described above. 10 or 1 μl of total lysate and 10 or 1 μg of OMVs were separated on Criterion™ TGX Stain-Free™ any kD™ gel (Bio-Rad, Hercules, California, USA) for Coomassie staining or Western Blot, respectively, together with a protein marker (PM2610, SMOBIO Technology, Inc.). Gels were stained with ProBlue Safe Stain Coomassie (Giotto Biotech, Sesto Fiorentino Firenze, Italy, EU). For Western Blot, proteins were transferred onto nitrocellulose filters using iBlot™ gel transfer system (Invitrogen). Filters were blocked in PBS with 10% skimmed milk and 0.05% Tween for 45 min. and then incubated in a 1:1000 dilution of the required immune sera in PBS with 3% skimmed milk and 0.05% Tween for 60 minutes. Polyclonal antibodies against OVA or SV40 were obtained from GenScript (GenScript, Piscataway, New Jersey, USA) by immunizing rabbits with CGQLESIINFEKLTE or VVYDFLKC synthetic peptide, respectively. Filters were then washed 3 times in PBS-0.05% Tween, incubated in a 1:2000 dilution of peroxidase-conjugated anti-rabbit immunoglobulin (Dako, Santa Clara, California, USA) in PBS with 3% skimmed milk and 0.05% Tween for 45 min., washed 3 times in PBS-Tween and once in PBS. Before acquiring the signals, filters were treated with Amersham™ ECL Select™ Western Blot Detection reagent (GE Heathcare, Chicago, Illinois, USA).

RESULTS

Oral Administration of EcN Engineered With a Cancer Epitope Elicit Cancer-Specific T Cells and Inhibits Tumor Growth

The human probiotic *E. coli* Nissle 1917 (33, 34) was engineered by fusing the SIINFEKL epitope (OVA), a MHC class I immunodominant peptide from chicken ovalbumin, to the C-terminus of the outer membrane-associated Braun's lipoprotein (Lpp) (35). The manipulation of the EcN chromosome was carried out using a variation of the previously described CRISPR/Cas9 protocols (18, 19), which allowed the in-frame insertion of the OVA sequence just upstream from the *lpp* stop codon (**Supplementary Figure 1**). The expression of the Lpp-OVA fusion in EcN (EcN(*lpp-OVA*)) was confirmed by SDS-PAGE and Western Blot analysis of total cell extract, using anti-OVA peptide antibodies (**Supplementary Figures 2A, B**).

Next, we assessed whether the oral administration of EcN(*lpp-OVA*) could elicit OVA-specific CD8+ T cells at the mucosal site. To this end, as shown in **Figure 1B**, either wild type EcN or EcN (*lpp-OVA*) (10^9 CFUs) were given by oral gavage to C57BL/6 mice three times at days 0, 3 and 6. One week after the last gavage mice were sacrificed and the presence of OVA-specific T cells in the *lamina propria* of small intestine was analyzed by flow cytometry. As shown in **Figure 1C**, the administration of EcN(*lpp-OVA*), but not of wild type EcN, elicited a significant fraction of OVA-specific CD8+ T cells in all treated mice (1.5-2.0% of total CD8+ T cells). No statistical difference of total CD3+, CD4+ and CD8+ T cells in *lamina propria* was observed between the two groups of mice treated with wild type EcN and EcN(*lpp-OVA*) (**Supplementary Figure 3** and **Supplementary Table 4**).

We then asked the question as to whether the administration of EcN(*lpp-OVA*) to C57BL/6 mice could influence the development of tumors when syngeneic OVA-B16F10 cells were injected subcutaneously. Mice were given either EcN or EcN(*lpp-OVA*) at days 0, 3 and 6 and one week after the last gavage all animals were challenged with $2.8×10^5$ OVA-B16F10 cells. Three additional gavages were then administered, the first one three days after the challenge, and the other two at one-week intervals (**Figure 1D**). As shown in **Figure 1E**, the administration of EcN(*lpp-OVA*) delayed tumor development with statistical significance (P=0.0079) compared to the treatment with EcN (and compared to PBS, **Supplementary Figure 4**).

Oral Administration of OMVs From E.coli Strains Engineered With Different CD8+ Epitopes Induces Epitope-Specific T Cell Responses and Inhibits Tumor Growth

Like all Gram-negative bacteria, EcN releases OMVs and since Lpp is a membrane-associated protein, Lpp-OVA fusion is expected to accumulate in the vesicular compartment. Therefore, the elicitation of the OVA-specific T cells observed after the oral administration of EcN(*lpp-OVA*) might be favored by the release of Lpp-OVA-decorated OMVs in the gut (Lpp-OVA-OMVs_EcN). Thanks to their small size (30 - 300 nm in diameter), these vesicles should be efficiently taken up by mucosal APCs, thus promoting the local elicitation of OVA-specific T cells responses. Moreover, OMVs can cross the intestinal epithelium and reach the bloodstream, thus potentially eliciting T cells in other secondary lymphoid organs (36, 37).

To test the possible contribution of microbiome-released OMVs in anti-tumor immunity, we first verified the production of OMVs by EcN(*lpp-OVA*) and the presence of the Lpp-OVA fusion protein in the vesicular compartment. EcN (*lpp-OVA*) was grown in liquid culture and at the end of the exponential growth the culture supernatant was subjected to ultracentrifugation and the pellet analyzed by SDS-PAGE. As shown in **Supplementary Figures 2A, B**, EcN(*lpp-OVA*) released OMVs, which carried a protein species of ~10 kDa recognized by antibodies specific for the OVA peptide.

Lpp-OVA-OMVs_EcN were then purified from EcN(*lpp-OVA*) grown in a bioreactor and orally administered to C57BL/6 mice

FIGURE 1 | Testing the role of molecular mimicry in tumor inhibition by oral administration of engineered probiotic bacteria. **(A)** *Schematic representation of the experimental strategy used to support the role of "molecular mimicry" in tumor inhibition*. *E. coli Nissle* was engineered with the OVA CD8$^+$ T cell epitope and the strain, or w.t. *E. coli Nissle*, were given to C57BL/6 mice by oral gavage. Animals were subsequently challenged with OVA-B16F10 cells and tumor growth was followed over time. **(B)** *Experimental setup for the analysis of OVA-specific T cells in the lamina propria*. 10^9 CFU of EcN and EcN(*lpp-OVA*) were given to C57BL/6 mice three times at three day intervals by gavage ("G"). One week after the last gavage, T cells ("TC") were isolated from the *lamina propria* and OVA-specific CD8$^+$ T cells were analyzed by flow cytometry. **(C)** *Flow cytometry analysis of OVA-specific CD8$^+$ T cells in lamina propria* – 1.5x10^6 cells were extracted from the *lamina propria* of C57BL/6 mice treated with EcN (blue) and EcN(*lpp-OVA*) (red) as described in **(B)**. The frequency of OVA-specific CD8$^+$ T cells was measured by using OVA$_{257-264}$ Dextramer-PE. Data from one single experiment (4 mice per group) **(D)** *Experimental setup to test tumor inhibition of by oral administration of EcN(lpp-OVA)*. EcN and EcN(*lpp-OVA*) were given at three day intervals to C57BL/6 mice by oral gavage ("G"). One week after the third gavage, mice were challenged ("C") with 2.8×10^5 OVA-B16F10 cells followed by three additional gavages. Tumor growth was followed over a period of 23 days and at the end of the experiment tumor infiltrating T cells (TILs) were analyzed. **(E)** *Analysis of tumor inhibition by EcN(lpp-OVA)*. Animals were treated as depicted in D, and tumor volumes were measured over time. Animals were sacrificed when tumors reach a volume of 1.500 mm^3. Combined data from two independent experiments (17 and 18 mice in control and vaccinated group, respectively). Statistical analysis was performed using Student's t-test (two-tailed). **P ≤ 0.01.

following the schedule reported in **Figure 2A**. One week after the last gavage, the animals were sacrificed and the presence of OVA-specific CD8$^+$ T cells in the *lamina propria* was analyzed. As shown in **Figure 2B**, 4 to 6% of all recovered CD8$^+$ T cells were OVA-specific.

Next, we asked the question as to whether Lpp-OVA-OMVs$_{EcN}$ could protect C57BL/6 mice from the challenge with OVA-B16F10 cells. The vesicles were administered five times by oral gavage following the schedule reported in **Figure 2G** and tumor growth was followed for 22 days after challenging mice with tumor cells one week after the third oral gavage. As shown

in **Figure 2H**, mice receiving Lpp-OVA-OMVs$_{EcN}$ showed a substantial reduction in tumor growth when compared to mice that received "empty" OMVs (OMVs$_{EcN}$) (P=0.0015) (or PBS, **Supplementary Figure 4**).

We also investigated whether the tumor inhibitory activity of OMVs carrying the OVA CD8$^+$ T cell epitope was restricted to vesicles released by EcN or rather vesicles from other *E. coli* strains could exert a similar function. To address this question, we fused the OVA epitope at the C-terminus of Lpp in the hyper-vesiculating *E. coli* BL21(DE3)Δ*ompA* strain (17).

FIGURE 2 | Effect of oral administration of OMVs on anti-tumor responses. **(A)** *Experimental protocol to analyze CD8⁺T cell responses after administration of OMVs engineered with T cell epitopes*. C57BL/6 mice were given three times 10 µg OMVs decorated with selected CD8⁺ T cell epitopes and one week after the last gavage epitope-specific T cells (TC) from *lamina propria* and/or intestinal epithelium (IEL) were analyzed by flow cytometry. **(B–F)** *Flow cytometry analysis of intestinal T cells*. Animals were given OMVs engineered with specific tumor epitopes as schematized in **(A)** and 1-2 x 10⁶ cells were isolated from the *lamina propria* **(B–E)** and intestinal epithelium **(F)** of the small intestine and the frequency of OVA-specific CD8⁺ T cells was measured by using epitope-specific Dextramer-PE (OVA, AH1 or SV40). As negative control, an unrelated dextramer SSYSYSSL was used (ctrl). Data from one single experiment with 5 mice per group (for control analysis, at least three mice per group were analyzed). **(G)** *Experimental protocol to study the tumor inhibitory activity of OMVs*. Mice were given OMVs by oral gavage **(G)** and were subsequently challenged with OVA-B16F10 tumor cells. Tumor growth was monitored for 23 days and during this period two additional gavages were administered. **(H, I)** *Analysis of OMV-mediated tumor inhibition*. C57BL/6 mice were treated with OMVs from wild type and OVA-expressing EcN and *E. coli* BL21(DE3)Δ*ompA* as depicted in G and tumor volumes were measured over a period of 25 days. Combined data from three (15 mice in total per group) and two (15 mice in total per group) independent experiments for **(H)** and **(I)**, respectively. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.

The OMVs expressing the Lpp-OVA fusion (**Supplementary Figures 2A, B**) were purified from *E. coli* BL21(DE3)Δ*ompA*(*lpp-OVA*) culture and administered by oral gavage to C57BL/6 mice following the schedule previously described. As shown in **Figure 2C**, Lpp-OVA-OMVs_Δ*ompA* elicited OVA-specific CD8⁺

T cells, which could be recovered from the *lamina propria*, and protected mice from OVA-B16F10 challenge compared to OMVs_Δ*ompA* (and compared to PBS, **Supplementary Figure 4**) to an extent similar to what observed with Lpp-OVA-OMVs_EcN (**Figure 2I**) (P=0.0023).

Finally, we tested whether orally administered OMVs decorated with CD8[+] T cell epitopes other than OVA could elicit epitope-specific T cells. To this aim, *E. coli* BL21 (DE3)$\Delta ompA$ was engineered with two other epitopes, the AH1 peptide (SPSYVYHQF), derived from the gp70 envelope protein of the CT26 murine colon carcinoma cell line (38) and the SV40 epitope IV T antigen peptide VVYDFLKL, efficiently presented by MHC I molecules in C57BL/6 mice (21, 22). To drive the expression of the epitopes in the OMVs, two plasmids were generated, pET-MBP-AH1 and pET-FhuD2-SV40. pET-MBP-AH1 encodes the AH1 peptide fused to the C-terminus of Maltose Binding Protein (MBP), while pET-FhuD2-SV40 expresses the SV40 peptide fused to the C-terminus of FhuD2 (39). MBP-AH1-OMVs$_{\Delta ompA}$ and FhuD2-SV40-OMVs$_{\Delta ompA}$ were purified from *E. coli* BL21(DE3)$\Delta ompA$(pET-MBP-AH1) and *E. coli* BL21(DE3)$\Delta ompA$(pET-FhuD2-SV40), respectively (**Supplementary Figures 2C, D**), and given three times, three days apart, by oral gavages to BALB/c and C57BL/6 mice, respectively (**Figure 2A**). One week after the last gavage, epitope-specific T cells were analyzed in the *lamina propria* and, in the case of SV40-C57BL/6, in the IELs population as well. As shown in **Figures 2D–F**, both OMVs elicited a relevant fraction of epitope-specific T cells, which could be detected both in the *lamina propria* and in the epithelium of the small intestine.

The Protective Activity of EcN and OMVs Engineered With a Tumor Epitope Is Mediated by Tumor Infiltration of Cancer-Specific CD8[+] T Cells

The data described so far indicate that intestinal bacteria and OMVs have a broad capacity to induce CD8[+] T cells against immunogenic epitopes in the gut and that the presence of these T cells is associated with tumor inhibition. Therefore, a plausible mechanism is that intestinal CD8[+] T cells disseminate systemically and reach the tumors.

To support this mechanism, at the end of the challenge experiments depicted in **Figures 1** and **2**, tumors from each group were surgically removed and the presence of total tumor infiltrating CD8[+] T cells and of infiltrating OVA-specific CD8[+] T cells was analyzed by flow cytometry (**Figure 3**; **Supplementary Figure 5** and **Supplementary Tables 5–7**). A similar number of total CD8[+] T cells was measured in tumors from animals despite of the treatment they received and no substantial difference was also observed in the total amount of CD3[+], CD4[+] and CD8[+] T cells (**Supplementary Figure 5** and **Supplementary Tables 5–7**). By contrast, the number of OVA-specific CD8[+] T cells was two- and three-fold higher in tumors from mice treated with bacteria and OMVs expressing the OVA antigen. The difference in the number of total and OVA-specific CD8[+] T cells in tumors was confirmed by immunofluorescence (IF) analysis by staining with fluorescence-labelled OVA dextramers one tumor from animals that received either EcN or EcN(*lpp-OVA*) (OVA[+] T cells/mm²: P = 0.0022; CD8[+] T cells/mm²: P > 0.05; CD8[+] T cells$_{EcN(lpp-OVA)}$/ CD8[+] T cells$_{EcN}$= 1.05; OVA-specific CD8[+] T cells$_{EcN(lpp-OVA)}$/ OVA-specific CD8[+] T cells$_{EcN}$ = 2.3) (**Figure 3**).

We also used IF to investigate whether a difference in regulatory T cells (T$_{REG}$) could be observed between the tumors from mice treated with EcN and EcN(*lpp-OVA*). To this aim, the same tumors described above were stained with a Rat monoclonal antibody anti-Mouse FoxP3-FITC conjugate. As shown in **Figure 3**, the number of FoxP3[+] cells was more than three-fold lower in the tumor from EcN(*lpp-OVA*)-treated mice (P=0.0002).

Taken together these data indicate the oral administration of EcN(*lpp-OVA*) promotes the modification of the tumor infiltrating T cells population by enhancing the frequency of the OVA-specific CD8[+] T cells and reducing the amount of FoxP3[+] cells. Although not experimentally tested, such FoxP3[+] cells likely belong to the CD4[+] T$_{REG}$ subset.

Analysis of CD8[+] T Cell Populations in the Lamina Propria and in the Tumor by TCR Sequencing

Having demonstrated that the oral administration of EcN(*lpp-OVA*) not only induced OVA-specific CD8[+] T cells, which could be isolated from the *lamina propria* but also increased the infiltration of OVA-specific CD8[+] T cells in tumors, we tried to address the question as to whether the two OVA-specific CD8[+] T cell populations might have a common origin. CD8[+] T cells were isolated from both intestines and tumors of animals treated with either EcN or EcN(*lpp-OVA*) (**Figure 4A**) and their TCR sequences were compared. The analysis of the β chain sequences revealed a relatively high clonality of T cells in the tumors from mice that received the EcN gavages, while the T cell population in the *lamina propria* compartment of the same animals was much less diversified, as highlighted by the values of the Inverse Simpson Index as a measure of immune diversity (**Figure 4B**). The administration of EcN(*lpp-OVA*) appeared to reduce the diversification of T cells clones in the tumors. To evaluate the presence of recirculating and potentially tumor-specific T lymphocytes, GLIPH2 algorithm was employed to detect antigen-specific receptors on the basis of CDR3 similarity. The algorithm identified a specific CDR3 motif commonly shared in the *lamina propria* and in the tumors of EcN(*lpp-OVA*)-treated mice. The presence of this specific motif was statistically significant when compared to its occurrence in a mouse reference dataset (**Supplementary Figure 6**). A deeper analysis of the TCR repertoire enabled the tracking of identical TCR sequences in different experimental groups. Interestingly, 11 TCR clonotypes were univocally present in the immune repertoire of T cells identified in the tumors and in the *lamina propria* of EcN(*lpp-OVA*)-treated mice. Five out of 11 TCR sequences could also be tracked in the tumors, but not in the *lamina propria*, of EcN-treated mice (**Figure 4C**).

Overall, our data indicate that tumors from EcN-treated mice were infiltrated with a relevant number of T cell clones carrying TCRs identical to *lamina propria*-associated T cells (**Figure 4C**), which were likely elicited by the gut microbiome. However, these T cells were incapable to control tumor growth. The oral administration of the microbial species EcN(*lpp-OVA*) expressing a tumor-specific T cell epitope (OVA), resulted in

FIGURE 3 | Continued

FIGURE 3 | *Analysis of Tumor Infiltrating Lymphocytes (TILs) by flow cytometry and immunofluorescence* – At the end of the experiment depicted in Figure 1D, tumors were collected and analyzed by flow cytometry and IF. The figure reports the flow cytometry analysis of OVA-specific CD8[+] T cells (one representative graph from the analysis performed on four tumors per group; for cell count, see details in **Supplementary Table 5**) and IF (one tumor from EcN **(A)** and one tumor from EcN(*lpp-OVA*) **(B)** group). For IF, tumors were fixed and frozen sections were analyzed for OVA-specific CD8[+] T cells (red stained cells) detection using OVA$_{257-264}$ Dextramer labeled with pycoerythryn. Total CD8[+] T cells (green stained cells) were also visualized by fixing frozen sections in acetone followed by incubation with anti-mouse CD8 rat monoclonal antibody and goat anti-rat Alexa-Fluor 488 conjugate antibody. FoxP3[+] cells were analyzed using Rat monoclonal antibody anti-Mouse FoxP3-FITC conjugate (green stained cells). The images report the analysis of FoxP3[+] cells with an overall view (bottom left) and three zoom-ins of the highlighted areas (bottom right). Numbers for T cell count/mm[2] represent the average and standard deviation from the analysis of 6 sections for CD8[+] and OVA[+] staining and 10 sections for FoxP3[+] staining, respectively.


FIGURE 4 | Analysis of TCR sequencing of CD8[+] T cells from *lamina propria* and tumors. **(A)** Schematic representation of the experimental protocol. Mice (5 animals/group) were treated as depicted and at the end of the experiment CD8[+] T cells were collected from the *lamina propria* and tumor of each animal. After RNA extraction, the TCR β subunit was subjected to sequence analysis. **(B)** Analysis of TCR β subunit diversity using the Inverse Simpson Index. The analysis was carried out after pooling the TCR sequences of each group (5 mice/group). The pie charts illustrate the different clonotypes identified in the tumors from EcN-treated mice (T-EcN) and from EcN(*lpp-OVA*)-treated mice (T-EcN(*lpp-OVA*)). **(C)** Heat map showing the sharing of identical CDR3 amino acid sequences among different experimental groups. Color legend indicates the frequency of the clonotypes measured as relative sequence count. T: tumor; LP: *lamina propria*.

the reorganization of the tumor infiltrating T cell population, with the concomitant enrichment of fewer T cell clones having TCRs identical to the TCRs of T cells found in the *lamina propria* and in the tumors of the same animals. Although not experimentally demonstrated, such T cells were probably those recognizing the OVA epitope.

Considering the low probability with which identical T cell clones can be independently generated at two different sites, the presence in *lamina propria* and tumors T cells with identical TCRs would imply that intestinal OVA-specific T cells reach the tumors *via* the blood stream. In an attempt to support this conclusion, two groups of animals were given three oral administrations of either $OMVs_{\Delta ompA}$ or Lpp-OVA-$OMVs_{\Delta ompA}$ one week apart and subsequently the presence of OVA-specific $CD8^+$ T cells was analyzed in spleens and blood. As shown in **Supplementary Figure 7**, an appreciable number of such T cells were found only in the spleens in the animals that received Lpp-OVA-$OMVs_{\Delta ompA}$.

Changes in Microbiome Composition After Oral Administration of EcN and OMV Treatment

In addition, or as an alternative, to the direct role of OVA-specific $CD8^+$ T cells, tumor inhibition could be mediated by modifications of the gut microbiome as a consequence of the oral gavages. To exclude this possibility, we followed the microbiome composition *via* shotgun metagenomics in animals that were given oral gavages with EcN, EcN(*lpp-OVA*), $OMVs_{EcN}$ and Lpp-OVA-$OMVs_{EcN}$ and were subsequently challenged with OVA-B16F10 cells (**Figure 5A**, see *Materials and Methods*). The microbiome composition of mice after three subsequent oral administrations of all formulations displayed some changes as assessed by Bray-Curtis beta-diversity estimations (**Figure 5B**). Even though normal microbiome fluctuations are expected to occur longitudinally, the microbiome variations between T_0 and T_1 were less pronounced in mice receiving vesicles than bacteria. However, this effect was not due to the colonization of EcN since *E. coli* showed low relative

FIGURE 5 | Effect of EcN, EcN(*lpp-OVA*), $OMVs_{EcN}$ and Lpp-OVA-$OMVs_{EcN}$ oral administration on gut microbiome composition. **(A)** *Schematic representation of the experimental procedure.* Mice were given three gavages (G) with either EcN, EcN(*lpp-OVA*), $OMVs_{EcN}$ or Lpp-OVA-$OMVs_{EcN}$. Mice were challenged with OVA-B16F10 cells (C) and then they received two (in the case of OMVs) or three additional oral administrations. Fecal samples were collected before the first gavage (T_0), before the tumor challenge (T_1) and at the end of the experiment (T_2) and fecal DNA was subjected to shotgut sequencing. **(B)** Microbiome diversity in all mice within each treatment group at different time points (T_0 *vs.* T_1 and T_0 *vs.* T_2) estimated as Bray-Curtis distance. Statistical differences between group pairs were calculated through Wilcoxon Rank Sum Test. **(C)** Heatmap representing the relative abundance of the top 30 most abundant bacterial species that showed statistical variation within each group at different time points (T_0 *vs.* T_1 and T_0 *vs.* T_2) (*P ≤ 0.05). **(D)** Venn diagram showing the overlap of species with significant variations in relative abundance between T_0 *vs.* T_1 (Wilcoxon Rank Sum Test P ≤ 0.05). The red circle highlights SGB43006, which increases at T_1 compared to T_0 in mice treated with EcN(*lpp-OVA*) and Lpp-OVA-$OMVs_{EcN}$.

abundances in all treatment groups (**Supplementary Figure 8**). Importantly, the oral administration of either EcN or EcN(*lpp-OVA*) influenced the microbiome composition in a similar manner between T_0 and T_1 and between T_0 and T_2, calculated as Bray-Curtis dissimilarity (P = 0.84 and P = 0.69, respectively). The same effect was also observed after the gavage with OMVs$_{EcN}$ or Lpp-OVA-OMVs$_{EcN}$ (P = 1 and P = 0.57, respectively, **Figure 5B**). Therefore, the presence of Lpp-OVA in both EcN and OMVs did not induce more marked changes in microbiome. In fact, our data support the opposite: the administration of EcN and OMVs$_{EcN}$ induced a significant change between T_0 and T_1 (PERMANOVA P = 0.009 and P = 0.048, respectively) while no significant effect was seen in EcN(*lpp-OVA*) or Lpp-OVA-OMVs$_{EcN}$ treated mice (PERMANOVA P = 0.105 and P = 0.057, respectively. Data not shown).

While the microbiome change patterns are less clear at T_2, potentially due to the tumor growth, this analysis provides evidence that the Lpp-OVA effect on tumor inhibition was not mediated by substantial overall changes of the microbiome. However, it could still be possible that specific taxa were directly or indirectly affected by the presence of the epitope. Considering the abundance of each microbial species we found several taxa that were significantly over- or under-represented (**Figure 5C**, Wilcoxon rank sum test, alpha 0.05). Nonetheless, little agreement was found on the panel of varying taxa among groups between T_0 and T_1 as shown by the heatmap in **Figure 5C**. In particular, among the groups that received a gavage with the OVA epitope, only one uncharacterized and yet-to-be cultivated species named SGB43006 was slightly significantly increasing at T_1 compared to T_0 (**Figure 5D**). SGB43006 abundance increased from 0.021% to 0.0395% in EcN(*lpp-OVA*) and from 0.0009% to 0.00946% in Lpp-OVA-OMVs$_{EcN}$.

Taken together the data would indicate that the presence or absence of OVA in both EcN and OMVs was irrelevant with respect to the way the gut microbiome was perturbed by the animal

treatment, thus strengthening the conclusion that the production of OVA-specific CD8$^+$ T cells plays a direct role in tumor inhibition.

OMVs Engineered With a Cancer Epitope Have a Therapeutic Effect Against Tumor Growth

We finally asked the question as to whether OMVs decorated with cancer-specific epitopes could have a therapeutic effect on already implanted tumors. To address this question we challenged C57BL/6 mice with OVA-B16F10 cells and subsequently animals were given five oral gavages of either OMVs$_{\Delta ompA}$ or Lpp-OVA-OMVs$_{\Delta ompA}$ over a period of 21 days (**Figure 6A**). As shown in **Figure 6B**, tumor growth in mice treated with Lpp-OVA-OMVs$_{\Delta ompA}$ was delayed in a statistically significant manner with respect to animals receiving "empty" OMVs$_{\Delta ompA}$ (P=0.0031). Moreover, while four out of five mice treated with OMVs$_{\Delta ompA}$ reached a near to death status and therefore were sacrificed, none of the Lpp-OVA-OMVs$_{\Delta ompA}$-treated mice were sacrificed before the end of the experiment.

DISCUSSION

The underpinning mechanisms through which microbes influence cancer growth remain to be fully elucidated. The observations that patients responding and non-responding to checkpoint inhibitors can be stratified based on their microbiome composition (40) and that the resistance to anti–PD-1 therapy in melanoma patients could be overcome by responder-derived fecal microbiota transplantation (FMT) (5) have prompted several laboratories to characterize the composition of the gut microbiome by 16S RNA/whole genome sequencing in search of microbial species with anti-

FIGURE 6 | Therapeutic effect of Lpp-OVA-OMVs$_{\Delta ompA}$. **(A)** *Schematic representation of the therapeutic experimental protocol*. C57BL/6 mice (5 animals/group) were challenged with OVA-B16F10 tumor cells and subsequently treated with five oral administrations (G) of either OMVs$_{\Delta ompA}$ or Lpp-OVA-OMVs$_{\Delta ompA}$ (10 μg/dose) over a period of 23 days. **(B)** *Analysis of tumor growth inhibition*. Tumor volumes were measured at three day intervals and the average of tumor volumes from each group is plotted over time. The graph in the inlet shows the survival curve of each group (according to the authorized protocol, animals were sacrificed when tumors reached a volume of 1.500 mm^3). (Panel **B**) report data from one experiment (4 and 5 mice in control and vaccinated group, respectively). Statistical analysis was performed using Student's t-test (two-tailed). **P ≤ 0.01.

tumor properties. *Enterococcus hirae*, *Bacteroides fragilis*, and *Akkermansia muciniphila* have been associated with favorable clinical outcome in cancer patients (7, 8, 40, 41) and recently a pool of eleven bacteria has been proposed as a potential probiotic therapy (42). However, from all published data a "consensus" list of "anti-tumor bacterial species" remains to be unambiguously defined and it is safe to say that all studies converge to the conclusion that an important property of a "healthy, anti-tumor" microbiome is its diversity.

Regarding how microbiome exerts the anti-tumor effects, proposed mechanisms envisage the production of specific metabolites and/or the stimulation at the mucosal level of inflammatory cytokines which can work in a paracrine manner (2, 6–8). Also, gut-derived bacteria have been isolated from tumors, where they can promote pro- and anti-tumor effects (43–48). Finally, the "molecular mimicry" hypothesis has been proposed (13, 49–53) holding that the anti-tumor effect of microbiome would be mediated by microbial-specific T cells, which accidentally recognize mutation-derived tumor neo-epitopes.

This work was conceptualized with the aim of demonstrating that cross-reactivity between the microbiome and cancer epitopes is involved in cancer immunity. We showed that when the human probiotic EcN expressing the OVA epitope was orally administered to C57BL/6 mice, high frequencies of OVA-specific T cells accumulated in the *lamina propria*. Moreover, oral delivery of EcN(*lpp-OVA*) reduced the growth of subcutaneous tumors in mice challenged with an OVA-B16F10 cell line. Importantly, tumor inhibition was associated with the elicitation of OVA-specific CD8[+] T cells which could be recovered from both the *lamina propria* and tumors, and our microbiome data supports the evidence that such T cells were the major players in the observed anti-tumor responses. As expected, the oral administration of both wild type EcN and EcN(*lpp-OVA*) modified the murine microbiome but the observed modifications were relatively modest and, importantly, not influenced by the expression of OVA in EcN. Even at the resolution of the shotgun sequencing, no specific single microbial species could be detected, which substantially differed from animals treated with wild type EcN and EcN(*lpp-OVA*). This would rule out the possibility that the anti-tumor activity of EcN(*lpp-OVA*) could be the result of an indirect effect acting on the alteration of other commensal species.

A question which remains to be fully addressed is the mechanism through which the oral administration of EcN(*lpp-OVA*) promoted the enrichment of OVA-specific CD8[+] T cells in the tumor environment. Our TCR sequencing data revealed the presence of T cell clones in the tumors and *lamina propria* T cells for EcN(*lpp-OVA*)-treated mice sharing identical TCRs, suggesting a common origin of these T cell populations. Therefore, the OVA-specific T cells induced by EcN(*lpp-OVA*) at the mucosal level could be disseminated systemically, eventually reaching tumor environment. Our data showing that OVA-specific T cells could be found in both the spleen and Peripheral Blood Mononuclear Cells (PBMCs) from mice receiving Lpp-OVA-OMVs$_{\Delta ompA}$ support this conclusion (**Supplementary Figure 7**).

An interesting observation emerging from our TCR sequencing data, is the high polyclonality of CD8[+] T cells isolated from tumors of animals that received wild type EcN and a relevant number of TILs share TCRs identical to those found in the *lamina propria*. When animals are treated with EcN (*lpp-OVA*) TILs polyclonality is reduced. This would support the notion that tumors can be infiltrated with "exhausted" T cells which are incapable of effectively eliminated tumor cells. Thus, reducing the abundances of such T cells through the administration of microbiome species carrying properly selected cross-reactive epitopes could be a way to potentiate anti-tumor immunity. In line with this, our IF analysis indicates that the tumors from animals treated with EcN(*lpp-OVA*) had a reduced number of FoxP3[+] T cells with respect to the tumors from EcN-treated mice (**Figure 3**).

OVA-specific CD8[+] T cells were also found in tumors from EcN-treated animals, in line with the fact the all animals were challenged with an OVA-B16F10 cell line. Therefore, the possibility that the high frequency of OVA-specific CD8[+] T cells observed in tumors of EcN(*lpp-OVA*)-treated mice was due to an amplification of locally induced T cells cannot be ruled out. As already pointed out, different microbial species have been isolated from animal and human tumors (54) and such species often have intestinal origin. These intra-tumor bacteria could induce T cells (55), which eventually recognize tumor-specific cross-reacting epitopes.

An interesting piece of information emerging from our study is the contribution of OMVs to the elicitation of CD8[+] T cells by intestinal bacteria. Oral delivery of OVA-OMVs derived from EcN(*lpp-OVA*) and *E. coli* BL21(DE3)Δ*ompA*(*lpp-OVA*) elicited high frequencies of OVA-specific CD8[+] T cells and protected mice from the challenge with OVA-B16F10 cells. The capacity of OMVs to stimulate intestinal CD8[+] T cells was not restricted to OVA as demonstrated by the isolation of CD8[+] T cells after oral administration of MBP-AH1-OMVs$_{\Delta ompA}$ in BALB/c mice and FhuD2-SV40-OMVs$_{\Delta ompA}$ in C57BL/6 mice.

OMVs are fascinating organelles released by all Gram-negative bacteria with a plethora of biological functions such as intra- and inter-species cross talk and bacteria-host interactions (56). Bacterial vesicles are known to be present in the intestine and they include both OMVs and vesicles produced by Gram-positive bacteria (57). In the gastrointestinal tract, OMVs are believed to contribute to maintaining the intestinal microbial ecosystem and mediating the delivery of bacterial effector molecules to host cells to modulate their physiology. Shen et al. (58) showed that intestinal *Bacteroides fragilis* releases OMVs decorated with capsular polysaccharide (PSA). Dendritic cells sense OMV-associated PSA through TLR2 and stimulate the production of regulatory T cells, which protect from autoimmune and/or inflammatory diseases. Moreover, OMVs produced by the major human gut commensal bacterium *Bacteroides thetaiotaomicron* (Bt) have been shown to be acquired by intestinal epithelial cells *via* dynamin-dependent endocytosis followed by intracellular trafficking to endo-lysosomal vesicles. OMVs$_{Bt}$ were also shown to transmigrate through epithelial cells *via* a paracellular route and to reach

systemic tissues, leading to suggest that OMVs may act as a long-distance microbiota–host communication system (37). The capacity of bacterial vesicles to disseminate systemically in the host and their potential dual role in tumor development and inhibition has been recently reviewed (59).

Our work provides evidence of a broader OMV function, which extends to cancer immunity *via* MM. Thanks to their small size, OMVs can navigate in the gut and be easily internalized by intestinal DCs. The pan-proteome of OMVs from all gut bacteria has the potential to generate a large repertoire of T cells, which act as sentinels to eliminate host cells in which mutations eventually generate cross-reacting immunogenic epitopes. Such immunological role of OMVs, and potentially of all vesicles released by intestinal bacteria, would underline how inseparable evolution has made mammals and their microbiota and humans may be viewed as a single unit of evolutionary selection comprised of a host and its associated microbes (58, 60).

One last comment deserves the translational potential of our work. Our data show that the oral delivery of OMVs protects mice from tumor challenge both in the prophylactic and therapeutic modalities. This leads to the attractive hypothesis that OMVs engineered with cancer neo-epitopes could be exploited, in combination with other therapies such as checkpoint inhibitors, to potentiate the elicitation of cancer-specific T cell responses. The ease with which OMVs can be manipulated with multiple epitopes (17, 20, 24, 39, 61, 62) and can be purified from the culture supernatant, make the production of personalized oral cancer vaccines particularly attractive.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are publicly available. This data can be found here: https://www.ncbi.nlm.nih.gov/sra/PRJNA851186.

ETHICS STATEMENT

The animal study was reviewed and approved by the Animal Ethical Committee of the University of Trento, by the Animal Ethical Committee of the Toscana Life Sciences and by the Italian Ministry of Health.

AUTHOR CONTRIBUTIONS

GG development of the overall concept, design of the research and writing of the manuscript. AGr coordination of

experimental activities. MB, SG, and LF engineering bacteria with OVA epitope. AGr, AGa, EC, and LF. OMVs engineering with SV40 and AH1 epitopes. MT, EC, MB, AGr, SG, and EK bacteria and OMVs preparations for oral administrations. EC, AGr, and ST: T cell analysis in *lamina propria* and tumors. MT, AGr, EC, IZ, EK, LC, SV, and EB animal experiments and tumor challenge models. GL, EC, GS, and AGr: immunofluorescence experiments and imaging analysis. FD coordination of immunofluorescence analysis. EC, MB, and IZ: DNA extraction for WGS analysis. NS management of microbiome and sequencing analysis, FAr: libraries preparation for WGS, MD: WGS bioinformatics analysis. EC and AGr: RNA extraction from CD8 T cell populations of *lamina propria* and tumors. ER: TCR sequencing and data analysis. EK, IZ, MB, and SG: figures editing. All: critical reading of the manuscript. All authors contributed to the article and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.912639/full#supplementary-material

REFERENCES

1. Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and Anticancer Immunosurveillance. *Cell* (2016) 165:276–87. doi: 10.1016/j.cell.2016.03.001
2. Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The Microbiome in Cancer Immunotherapy: Diagnostic Tools and Therapeutic Strategies. *Science* (2018) 359:1366–70. doi: 10.1126/science.aar6918
3. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal *Bifidobacterium* Promotes Antitumor Immunity and Facilitates Anti-PD-L1 Efficacy. *Science* (2015) 350:1084–9. doi: 10.1126/science.aac4255
4. Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G. The Gut Microbiota Influences Anticancer Immunosurveillance and General Health. *Nat Rev Clin Oncol* (2018) 15:382–96. doi: 10.1038/s41571-018-0006-2

5. Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, et al. Fecal Microbiota Transplant Overcomes Resistance to Anti-PD-1 Therapy in Melanoma Patients. *Science* (2021) 371:595–602. doi: 10.1126/science.abf3363

6. Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, et al. Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. *Cancer Cell* (2016) 30:147–60. doi: 10.1016/j.ccell.2016.05.016

7. Daillère R, Vétizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, et al. *Enterococcus Hirae* and *Barnesiella Intestinihominis* Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. *Immunity* (2016) 45:931–43. doi: 10.1016/j.immuni.2016.09.009

8. Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer Immunotherapy by CTLA-4 Blockade Relies on the Gut Microbiota. *Science* (2015) 350:1079–84. doi: 10.1126/science.aad1329

9. Cook DP, Cunha JPMCM, Martens PJ, Sassi G, Mancarella F, Ventriglia G, et al. Intestinal Delivery of Proinsulin and IL-10 *via Lactococcus Lactis* Combined With Low-Dose Anti-CD3 Restores Tolerance Outside the Window of Acute Type 1 Diabetes Diagnosis. *Front Immunol* (2020) 11:1103. doi: 10.3389/fimmu.2020.01103

10. Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, Remark R, et al. Identification of Unique Neoantigen Qualities in Long-Term Survivors of Pancreatic Cancer. *Nature* (2017) 551:512–6. doi: 10.1038/nature24462

11. Bresciani A, Paul S, Schommer N, Dillon MB, Bancroft T, Greenbaum J, et al. T-Cell Recognition is Shaped by Epitope Sequence Conservation in the Host Proteome and Microbiome. *Immunology* (2016) 148:34–9. doi: 10.1111/imm.12585

12. Pro SC, Lindestam Arlehamn CS, Dhanda SK, Carpenter C, Lindvall M, Faruqi AA, et al. Microbiota Epitope Similarity Either Dampens or Enhances the Immunogenicity of Disease-Associated Antigenic Epitopes. *PloS One* (2018) 13:e0196551. doi: 10.1371/journal.pone.0196551

13. Gil-Cruz C, Perez-Shibayama C, de Martin A, Ronchi F, van der Borght K, Niederer R, et al. Microbiota-Derived Peptide Mimics Drive Lethal Inflammatory Cardiomyopathy. *Science* (2019) 366:881–6. doi: 10.1126/science.aav3487

14. Bessell CA, Isser A, Havel JJ, Lee S, Bell DR, Hickey JW, et al. Commensal Bacteria Stimulate Antitumor Responses *via* T Cell Cross-Reactivity. *JCI Insight* (2020) 5:e135597. doi: 10.1172/jci.insight.135597

15. Fluckiger A, Daillère R, Sassi M, Sixt BS, Liu P, Loos F, et al. Cross-Reactivity Between Tumor MHC Class I–restricted Antigens and an Enterococcal Bacteriophage. *Science* (2020) 369:936–42. doi: 10.1126/science.aax0701

16. Tomasi M, Dalsass M, Beghini F, Zanella I, Caproni E, Fantappiè L, et al. Commensal *Bifidobacterium* Strains Enhance the Efficacy of Neo-Epitope Based Cancer Vaccines. *Vaccines* (2021) 9:1–19. doi: 10.3390/vaccines9111356

17. Fantappiè L, de Santis M, Chiarot E, Carboni F, Bensi G, Jousson O, et al. Antibody-Mediated Immunity Induced by Engineered *Escherichia Coli* OMVs Carrying Heterologous Antigens in Their Lumen. *J Extracell Vesicles* (2014) 3:24015. doi: 10.3402/jev.v3.24015

18. Zerbini F, Zanella I, Fraccascia D, König E, Irene C, Frattini LF, et al. Large Scale Validation of an Efficient CRISPR/Cas-Based Multi Gene Editing Protocol in *Escherichia Coli*. *Microb Cell Factories* (2017) 16:1–18. doi: 10.1186/s12934-017-0681-1

19. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression. *Cell* (2013) 152:1173–83. doi: 10.1016/j.cell.2013.02.022

20. Grandi A, Fantappiè L, Irene C, Valensin S, Tomasi M, Stupia S, et al. Vaccination With a FAT1-Derived B Cell Epitope Combined With Tumor-Specific B and T Cell Epitopes Elicits Additive Protection in Cancer Mouse Models. *Front Oncol* (2018) 8:481. doi: 10.3389/fonc.2018.00481

21. Mylin LM, Schell TD, Roberts D, Epler M, Boesteanu A, Collins EJ, et al. Quantitation of CD8+ T-Lymphocyte Responses to Multiple Epitopes From Simian Virus 40 (SV40) Large T Antigen in C57BL/6 Mice Immunized With SV40, SV40 T-Antigen-Transformed Cells, or Vaccinia Virus Recombinants Expressing Full-Length T Antigen or Epitope. *J Virol* (2000) 74:6922–34. doi: 10.1128/jvi.74.15.6922-6934.2000

22. Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MTS, Freschi M, et al. Peripheral T Cell Tolerance Occurs Early During Spontaneous Prostate Cancer Development and can be Rescued by Dendritic Cell Immunization. *Eur J Immunol* (2005) 35:66–75. doi: 10.1002/eji.200425531

23. Klock HE, Lesley SA. The Polymerase Incomplete Primer Extension (PIPE) Method Applied to High-Throughput Cloning and Site-Directed Mutagenesis. *Methods Mol Biol* (2009) 498:91–103. doi: 10.1007/978-1-59745-196-3_6

24. Zanella I, König E, Tomasi M, Gagliardi A, Frattini L, Fantappiè L, et al. Proteome-Minimized Outer Membrane Vesicles From *Escherichia Coli* as a Generalized Vaccine Platform. *J Extracell Vesicles* (2021) 10:e12066. doi: 10.1002/jev2.12066

25. Faucher P, Beuvon F, Fignani D, Sebastiani G, Afonso G, Zhou Z, et al. Immunoregulated Insulitis and Slow-Progressing Type 1 Diabetes After Duodenopancreatectomy. *Diabetologia* (2021) 64:2731–40. doi: 10.1007/s00125-021-05563-8

26. Takiishi T, Cook DP, Korf H, Sebastiani G, Mancarella F, Cunha JPMCM, et al. Reversal of Diabetes in NOD Mice by Clinical-Grade Proinsulin and IL-10'secreting *Lactococcus Lactis* in Combination With Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells. *Diabetes* (2017) 66:448–59. doi: 10.2337/db15-1625

27. Takiishi T, Ding L, Baeke F, Spagnuolo I, Sebastiani G, Laureys J, et al. Dietary Supplementation With High Doses of Regular Vitamin D3 Safely Reduces Diabetes Incidence in NOD Mice When Given Early and Long Term. *Diabetes* (2014) 63:2026–36. doi: 10.2337/db13-1559

28. Bolotin DA, Mamedov IZ, Britanova OV, Zvyagin IV, Shagin D, Ustyugova SV, et al. Next Generation Sequencing for TCR Repertoire Profiling: Platform-Specific Features and Correction Algorithms. *Eur J Immunol* (2012) 42:3073–83. doi: 10.1002/eji.201242517

29. Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva EV, et al. MiXCR: Software for Comprehensive Adaptive Immunity Profiling. *Nat Methods* (2015) 12:380–1. doi: 10.1038/nmeth.3364

30. Huang H, Wang C, Rubelt F, Scriba TJ, Davis MM. Analyzing the *Mycobacterium Tuberculosis* Immune Response by T-Cell Receptor Clustering With GLIPH2 and Genome-Wide Antigen Screening. *Nat Biotechnol* (2020) 38:1194–202. doi: 10.1038/s41587-020-0505-4

31. Langmead B, Salzberg SL. Fast Gapped-Read Alignment With Bowtie 2. *Nat Methods* (2012) 9:357–9. doi: 10.1038/nmeth.1923

32. Beghini F, McIver LJ, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, et al. Integrating Taxonomic, Functional, and Strain-Level Profiling of Diverse Microbial Communities With Biobakery 3. *eLife* (2021) 10:e65088. doi: 10.7554/eLife.65088

33. Sonnenborn U. *Escherichia Coli* Strain Nissle 1917-From Bench to Bedside and Back: History of a Special Escherichia Coli Strain With Probiotic Properties. *FEMS Microbiol Lett* (2016) 363:fnw212. doi: 10.1093/femsle/fnw212

34. Lasaro M, Liu Z, Bishar R, Kelly K, Chattopadhyay S, Paul S, et al. *Escherichia Coli* Isolate for Studying Colonization of the Mouse Intestine and its Application to Two-Component Signaling Knockouts. *J Bacteriol* (2014) 196:1723–32. doi: 10.1128/JB.01296-13

35. Li GW, Burkhardt D, Gross C, Weissman JS. Quantifying Absolute Protein Synthesis Rates Reveals Principles Underlying Allocation of Cellular Resources. *Cell* (2014) 157:624–35. doi: 10.1016/j.cell.2014.02.033

36. Tulkens J, Vergauwen G, Van Deun J, Geeurickx E, Dhondt B, Lippens L, et al. Increased Levels of Systemic LPS-Positive Bacterial Extracellular Vesicles in Patients With Intestinal Barrier Dysfunction. *Gut* (2020) 69:191–3. doi: 10.1136/gutjnl-2018-317726

37. Jones EJ, Booth C, Fonseca S, Parker A, Cross K, Miquel-Clopés A, et al. The Uptake, Trafficking, and Biodistribution of *Bacteroides Thetaiotaomicron* Generated Outer Membrane Vesicles. *Front Microbiol* (2020) 11:57. doi: 10.3389/fmicb.2020.00057

38. Huang AYC, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, et al. The Immunodominant Major Histocompatibility Complex Class I-Restricted Antigen of a Murine Colon Tumor Derives From an Endogenous Retroviral Gene Product. *Proc Natl Acad Sci USA* (1996) 93:9730–5. doi: 10.1073/pnas.93.18.9730

39. Irene C, Fantappiè L, Caproni E, Zerbini F, Anesi A, Tomasi M, et al. Bacterial Outer Membrane Vesicles Engineered With Lipidated Antigens as a Platform for *Staphylococcus Aureus* Vaccine. *Proc Natl Acad Sci USA* (2019) 116:21780–8. doi: 10.1073/pnas.1905112116

40. Routy B, Le CE, Derosa L, Duong CPM, MT A, Daillère R, et al. Gut Microbiome Influences Efficacy of PD-1–Based Immunotherapy Against Epithelial Tumors. *Science* (2018) 359:91–7. doi: 10.1126/science. aan3706

41. Rong Y, Dong Z, Hong Z, Jin Y, Zhang W, Zhang B, et al. Reactivity Toward *Bifidobacterium Longum* and *Enterococcus Hirae* Demonstrate Robust CD8⁺ T Cell Response and Better Prognosis in HBV-Related Hepatocellular Carcinoma. *Exp Cell Res* (2017) 358:352–9. doi: 10.1016/ j.yexcr.2017.07.009

42. Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y, et al. A Defined Commensal Consortium Elicits CD8 T Cells and Anti-Cancer Immunity. *Nature* (2019) 565:600–5. doi: 10.1038/s41586-019-0878-z

43. Silva-Valenzuela CA, Desai PT, Molina-Quiroz RC, Pezoa D, Zhang Y, Porwollik S, et al. Solid Tumors Provide Niche-Specific Conditions That Lead to Preferential Growth of. *Salmonella Oncotarget* (2016) 7:35169–80. doi: 10.18632/oncotarget.9071

44. Hieken TJ, Chen J, Hoskin TL, Walther-Antonio M, Johnson S, Ramaker S, et al. The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease. *Sci Rep* (2016) 6:30751. doi: 10.1038/srep30751

45. Jin C, Lagoudas GK, Zhao C, Blainey PC, Fox JG, Jacks T, et al. Commensal Microbiota Promote Lung Cancer Development *via* Gd T Cells. *Cell* (2019) 176:998–1013. doi: 10.1016/j.cell.2018.12.040

46. Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, et al. The Human Tumor Microbiome Is Composed of Tumor Type-Specific Intracellular Bacteria. *Science* (2020) 368:973–80. doi: 10.1126/science.aay9189

47. Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, et al. Potential Role of Intratumor Bacteria in Mediating Tumor Resistance to the Chemotherapeutic Drug Gemcitabine. *Science* (2017) 357:1156–60. doi: 10.1126/science.aah5043

48. Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, Mishra A, et al. The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. *Cancer Discov* (2018) 8:403–16. doi: 10.1158/2159-8290.CD-17-1134

49. Rubio-Godoy V, Dutoit V, Zhao Y, Simon R, Guillaume P, Houghten R, et al. Positional Scanning-Synthetic Peptide Library-Based Analysis of Self- and Pathogen-Derived Peptide Cross-Reactivity With Tumor-Reactive Melan-A-Specific CTL. *J Immunol* (2002) 169:5696–707. doi: 10.4049/ jimmunol.169.10.5696

50. Vujanovic L, Mandic M, Olson WC, Kirkwood J, Storkus WJ. A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses Against Tumor Antigen MAGE-A6. *Clin Cancer Res* (2007) 13:6796–806. doi: 10.1158/1078-0432.CCR-07-1909

51. Perez-Muñoz ME, Joglekar P, Shen YJ, Chang KY, Peterson DA. Identification and Phylogeny of the First T Cell Epitope Identified From a Human Gut Bacteroides Species. *PloS One* (2015) 10:e0144382. doi: 10.1371/ journal.pone.0144382

52. Yang Y, Torchinsky MB, Gobert M, Xiong H, Xu M, Linehan JL, et al. Focused Specificity of Intestinal TH17 Cells Towards Commensal Bacterial Antigens. *Nature* (2014) 510:152–6. doi: 10.1038/nature13279

53. Chai JN, Peng Y, Rengarajan S, Solomon BD, Ai TL, Shen Z, et al. *Helicobacter* Species are Potent Drivers of Colonic T Cell Responses in Homeostasis and Inflammation. *Sci Immunol* (2017) 2:eaal5068. doi: 10.1126/sciimmunol.aal5068

54. Atreya CE, Turnbaugh PJ. Probing the Tumor Micro(B)Environment. *Science* (2020) 368:938–9. doi: 10.1126/science.abc1464

55. Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E, et al. Identification of Bacteria-Derived HLA-Bound Peptides in Melanoma. *Nature* (2021) 592:138–43. doi: 10.1038/s41586-021-03368-8

56. Kulp A, Kuehn MJ. Biological Functions and Biogenesis of Secreted Bacterial Outer Membrane Vesicles. *Annu Rev Microbiol* (2010) 64:163–84. doi: 10.1146/annurev.micro.091208.073413

57. Park KS, Lee J, Lee C, Park HT, Kim JW, Kim OY, et al. Sepsis-Like Systemic Inflammation Induced by Nano-Sized Extracellular Vesicles From Feces. *Front Microbiol* (2018) 9:1735. doi: 10.3389/fmicb.2018.01735

58. Shen Y, Torchia MLG, Lawson GW, Karp CL, Ashwell JD, Mazmanian SK. Outer Membrane Vesicles of a Human Commensal Mediate Immune Regulation and Disease Protection. *Cell Host Microbe* (2012) 12:509–20. doi: 10.1016/j.chom.2012.08.004

59. Chronopoulos A, Kalluri R. Emerging Role of Bacterial Extracellular Vesicles in Cancer. *Oncogene* (2020) 39:6951–60. doi: 10.1038/s41388-020-01509-3

60. Rosenberg E, Sharon G, Zilber-Rosenberg I. The Hologenome Theory of Evolution Contains Lamarckian Aspects Within a Darwinian Framework. *Environ Microbiol* (2009) 11(12):2959–62. doi: 10.1111/j.1462-2920.2009.01995.x

61. Grandi A, Tomasi M, Zanella I, Ganfini L, Caproni E, Fantappiè L, et al. Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles. *Front Oncol* (2017) 7:253. doi: 10.3389/ fonc.2017.00253

62. Fantappiè L, Irene C, De Santis M, Armini A, Gagliardi A, Tomasi M, et al. Some Gram-Negative Lipoproteins Keep Their Surface Topology When Transplanted From One Species to Another and Deliver Foreign Polypeptides to the Bacterial Surface. *Mol Cell Proteomics* (2017) 16:1348–64. doi: 10.1074/mcp.M116.065094